Orizuru Therapeutics
Regenerative medicine company spun out of the Takeda-Kyoto University CiRA collaboration in April 2021, developing allogeneic iPSC-derived cell therapies for diabetes, heart disease and other indications, and building the manufacturing platforms required to commercialise them.
Headquarters
Fujisawa, Japan
Year Founded
2021
Founders
Takeda-Kyoto University CiRA joint venture; Kenji Nonaka (Representative Director), Shinya Yamanaka (board)
Country
Japan
Financial Information
Funding Stage
Series B
Recent Funding
$40M
Funding By
Kyoto University Innovation Capital, Takeda Pharmaceutical, SMBC Venture Capital, MUFG Bank, MEDIPAL Holdings, Nippon Venture Capital, T1D Fund
Core Technology
iPSC-derived allogeneic cell therapy platforms with scale-up manufacturing
Product Type
Cell Therapy
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: Not disclosed
- FDA/EMA Status: N/A
- Clinical Trial Registration: Not disclosed
- Patents / IP Status: Licensed from the Takeda-CiRA research program
Partnerships
Pharma Collaborations
Takeda Pharmaceutical (co-founder and shareholder)
Academic / Hospital Tie-ups
Kyoto University CiRA (Center for iPS Cell Research and Application)
CRO/CDMO Partnerships
In-house manufacturing development
Market & Differentiation
Inherits the CiRA iPSC platform and Yamanaka laboratory science with pharma-scale backing